O16-2 Phase I trial of NY-ESO-1 TCR-T cell therapy combined with nanoparticulate vaccine but without lymphodepletion for STS

Mikiya Ishihara,Yoshihiro Nishida,Shigehisa Kitano,Akira Kawai,Naozumi Harada,Yoshihiro Miyahara,Hiroyoshi Hattori,Kohichi Takada,Makoto Emori,Shigeki Kakunaga,Makoto Endo,Yoshihiro Matsumoto,Tetsuro Sasada,Eiichi Sato,Tomomi Yamada,Akihiko Matsumine,Yasuhiro Nagata,Shinichi Kageyama,Hiroshi Shiku

Annals of Oncology（2023）

引用 0|浏览4

暂无评分

摘要

We conducted an investigator-initiated, multi-institutional first-in-human phase I clinical trial of a NY-ESO-1-specific TCR engineered T cell (TBI-1301) combined with a T cell stimulator CHP:NE1 for patients with NY-ESO-1-expressing advanced soft tissue sarcoma (STS).

查看译文

关键词

nanoparticulate vaccine,lymphodepletion,ny-eso

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要